公开(公告)号：US20200375990A1

公开(公告)日：2020-12-03

申请号：US16924082

申请日：2020-07-08

Applicant: Viracta Therapeutics Inc.

Inventor： Robert MCRAE ,  Gail L. BROWN ,  Xiaohu DENG ,  David SLACK ,  Marshelle Smith WARREN ,  Richard TRAUGER

IPC: A61K31/506 ,  A61K31/522 ,  A61P35/00

Abstract: Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.

公开(公告)号：US20230113598A1

公开(公告)日：2023-04-13

申请号：US17814224

申请日：2022-07-21

Applicant: Viracta Therapeutics, Inc. ,  Millennium Pharmaceuticals, Inc.

Inventor： Joseph ARNDT ,  Timothy Chan ,  Kevin Guckian ,  Gnanasambandam Kumaravel ,  Wen-Cheng Lee ,  Edward Yin-Shiang Lin ,  Daniel Scott ,  Lihong Sun ,  Jermaine Thomas ,  Kurt Van Vloten ,  Deping Wang ,  Lei Zhang ,  Daniel Erlanson

IPC: C07D471/04 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D519/00 ,  C07D241/28 ,  C07D498/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383

Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

公开(公告)号：US10857152B2

公开(公告)日：2020-12-08

申请号：US15959482

申请日：2018-04-23

Applicant: VIRACTA THERAPEUTICS, INC. ,  TRUSTEES OF BOSTON UNIVERSITY

Inventor： Ronald J. Berenson ,  Douglas V. Faller

IPC: A61K31/506 ,  A61K31/52 ,  A61K31/522 ,  A61K31/167 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/513 ,  A61K45/06 ,  A61K38/12 ,  A61K31/18 ,  A61K9/00 ,  A61K31/165 ,  A61K31/473 ,  A61K31/4402 ,  A61K38/15

Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

公开(公告)号：US20200368280A1

公开(公告)日：2020-11-26

申请号：US16961200

申请日：2019-01-11

Applicant: Viracta Therapeutics, Inc.

Inventor： Marshelle WARREN ,  Preston DANIELS

IPC: A61K35/17 ,  A61P35/02 ,  A61K31/506 ,  A61K39/395 ,  A61P31/18 ,  C12N5/0783

Abstract: Described herein are methods and compositions useful for augmenting cell-based immunotherapies. The augmented cell-based immunotherapies can be used to treat individuals with cancer and chronic viral infections.

公开(公告)号：US20240417389A1

公开(公告)日：2024-12-19

申请号：US18813750

申请日：2024-08-23

Applicant: Viracta Therapeutics, Inc. ,  Biogen MA Inc.

Inventor： Brian T. HOPKINS ,  Timothy R. CHAN ,  Tracy J. JENKINS ,  Patrick CONLON ,  Xiongwei CAI ,  Michael HUMORA ,  Xianglin SHI ,  Ross A. MILLER ,  Andrew THOMPSON

IPC: C07D401/14

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

公开(公告)号：US20240342172A1

公开(公告)日：2024-10-17

申请号：US17314550

申请日：2021-05-07

Applicant: VIRACTA THERAPEUTICS, INC. ,  TRUSTEES OF BOSTON UNIVERSITY

Inventor： Ronald J. Berenson ,  Douglas V. Faller

IPC: A61K31/506 ,  A61K9/00 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06 ,  Y02A50/30

Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

公开(公告)号：US20230099829A1

公开(公告)日：2023-03-30

申请号：US17831041

申请日：2022-06-02

Applicant: Viracta Therapeutics, Inc.

Inventor： Stig K. HANSEN ,  Minke E. BINNERTS

IPC: A61K31/497 ,  A61K31/506 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/519 ,  A61K31/517 ,  A61P35/02

Abstract: Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.

公开(公告)号：US20240294524A1

公开(公告)日：2024-09-05

申请号：US18632638

申请日：2024-04-11

Applicant: Viracta Therapeutics, Inc. ,  Millennium Pharmaceuticals, Inc.

Inventor： Joseph ARNDT ,  Timothy CHAN ,  Kevin GUCKIAN ,  Gnanasambandam KUMARAVEL ,  Wen-Cherng LEE ,  Edward Yin-Shiang LIN ,  Daniel SCOTT ,  Lihong SUN ,  Jermaine THOMAS ,  Kurt VAN VLOTEN ,  Deping WANG ,  Lei ZHANG ,  Daniel ERLANSON

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D241/28 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D498/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D241/28 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

公开(公告)号：US20230174511A1

公开(公告)日：2023-06-08

申请号：US17883202

申请日：2022-08-08

Applicant: Viracta Therapeutics, Inc. ,  Biogen MA Inc.

Inventor： Brian T. HOPKINS ,  Timothy R. CHAN ,  Tracy J. JENKINS ,  Patrick CONLON ,  Xiongwei CAI ,  Michael HUMORA ,  Xianglin SHI ,  Ross A. MILLER ,  Andrew THOMPSON

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton’s tyrosine kinase and which exhibit desirable characteristics for the same.

公开(公告)号：US20230046457A1

公开(公告)日：2023-02-16

申请号：US17743214

申请日：2022-05-12

Applicant: Viracta Therapeutics, Inc. ,  Biogen MA Inc.

Inventor： Minna BUI ,  Patrick CONLON ,  Julio H. CUERVO ,  Daniel A. ERLANSON ,  Junfa FAN ,  Bing GUAN ,  Brian T. HOPKINS ,  Tracy J. JENKINS ,  Gnanasambandam KUMARAVEL ,  Alexey A. LUGOVSKOY ,  Doug MARCOTTE ,  Noel POWELL ,  Daniel SCOTT ,  Laura SILVIAN ,  Art TAVERAS ,  Deping WANG ,  Min ZHONG

IPC: C07D487/14 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.